MediWound Ltd. (NASDAQ:MDWD) – Analysts at Jefferies Group cut their Q3 2017 earnings estimates for MediWound in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now expects that the biopharmaceutical company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.16). Jefferies Group also issued estimates for MediWound’s FY2017 earnings at ($0.81) EPS, FY2018 earnings at ($0.85) EPS and FY2019 earnings at ($0.84) EPS.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 240.54%. MediWound’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.34) earnings per share.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Weighs in on MediWound Ltd.’s Q3 2017 Earnings (NASDAQ:MDWD)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at

A number of other equities research analysts also recently weighed in on MDWD. Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the stock a “buy” rating in a report on Monday, May 8th. Aegis reissued a “buy” rating and set a $11.00 target price on shares of MediWound in a report on Thursday, May 25th. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a report on Monday, June 26th. Finally, Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $10.19.

MediWound (NASDAQ MDWD) opened at 6.80 on Monday. The firm’s market capitalization is $149.12 million. MediWound has a 1-year low of $4.25 and a 1-year high of $8.58. The company’s 50-day moving average is $6.96 and its 200 day moving average is $6.41.

Several large investors have recently bought and sold shares of MDWD. Renaissance Technologies LLC increased its stake in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN increased its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the period. Finally, Wellington Management Group LLP increased its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the period. 27.32% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with's FREE daily email newsletter.